4DMedical Joins All Ordinaries Index as Passive Funds Prepare to Buy Stock

By

Key Takeaways

4DMedical's All Ordinaries Index Addition takes effect 23 March 2026, potentially triggering institutional buying as index-tracking funds rebalance to include the ASX-listed respiratory imaging company.

  • 4DMedical (ASX: 4DX) will be added to the S&P/ASX All Ordinaries Index prior to market open on 23 March 2026 as part of the March 2026 quarterly rebalance.
  • The inclusion confirms 4DMedical has met the minimum float-adjusted market capitalisation and liquidity thresholds required to join Australia's broadest equities benchmark.
  • Index-tracking funds and ETFs replicating the All Ordinaries may be required to purchase 4DX shares, potentially increasing trading volumes and broadening the shareholder register.
  • The rebalance affects 77 stocks in total, with 43 additions and 34 removals reflecting shifts in market capitalisation and liquidity across Australian equities.

4DMedical will be added to the S&P/ASX All Ordinaries Index prior to market open on Monday, 23 March 2026, following S&P Dow Jones Indices’ March 2026 quarterly rebalance. The 4DMedical All Ordinaries Index Addition signals the respiratory imaging company has met the size and liquidity thresholds required for inclusion in Australia’s broadest equities benchmark.

The announcement positions 4DMedical (ASX: 4DX) among 43 companies gaining entry to the index, whilst 34 stocks will be removed as part of the quarterly review.

4DMedical joins Australia’s broadest equities benchmark

S&P Dow Jones Indices confirmed the change will take effect prior to trading on 23 March 2026, marking formal recognition of 4DMedical’s growing market presence. The company joins the All Ordinaries as part of the March 2026 quarterly rebalance, which adjusts index composition based on updated market capitalisation and liquidity metrics.

Index inclusion follows the company’s commercialisation of its proprietary XV Technology™ lung imaging platform. The addition reflects 4DMedical’s market position within Australia’s healthcare technology sector.

What is the All Ordinaries Index?

The All Ordinaries is Australia’s oldest and most comprehensive share market index, tracking approximately 500 of the largest ASX-listed companies by market capitalisation. Launched in January 1980, it serves as a broad benchmark for Australian equities performance across all sectors.

Key characteristics include:

  • Represents approximately 95% of the ASX’s domestic equity market capitalisation
  • Rebalanced quarterly to reflect changes in company size and trading activity
  • Used as the underlying benchmark for numerous passive investment products
  • Inclusion requires meeting minimum float-adjusted market capitalisation and liquidity criteria

How index inclusion benefits shareholders

Index-tracking funds and exchange-traded products that replicate the All Ordinaries may now be required to purchase 4DX shares to maintain accurate benchmark alignment. This mechanical buying can increase trading liquidity and broaden the shareholder register beyond active investors.

Three potential benefits for investors include:

  1. Enhanced liquidity: Index funds rebalancing positions may increase daily trading volumes and reduce bid-ask spreads
  2. Institutional visibility: Portfolio managers benchmarking against the All Ordinaries gain automatic exposure to the company’s performance
  3. Broader ownership: Passive investment vehicles bring long-term, index-weighted capital to the register

The rebalance affects 77 stocks in total, with 43 additions and 34 removals reflecting shifts in market capitalisation and liquidity across Australian equities.

4DMedical’s market position

4DMedical develops lung imaging technology using its proprietary XV Technology™ platform, which provides functional respiratory imaging for clinical and research applications. The company has been commercialising its technology across hospital networks and research institutions.

The All Ordinaries Index addition represents a milestone reflecting the company’s growth trajectory as it continues deploying its respiratory imaging platform. Index inclusion does not alter the company’s operational strategy or clinical development programmes.

What comes next

The transition occurs prior to market open on 23 March 2026, with S&P Dow Jones Indices implementing changes before the first trades of the session. Investors may observe trading volume changes around the effective date as index funds execute rebalancing transactions to align portfolios with the updated benchmark composition.

Index-tracking products typically complete rebalancing trades within the first few sessions following implementation, though timing varies by fund structure and rebalancing methodology. The company’s ongoing focus remains on commercialising its XV Technology™ platform across target healthcare markets.

Want the Next Healthcare Tech Breakout in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements and expert coverage delivered straight to your inbox the moment news breaks.


Share Article:
John Zadeh
By John Zadeh
Founder & CEO
John Zadeh is a seasoned small-cap investor and digital media entrepreneur with over 10 years of experience in Australian equity markets. As Founder and CEO of StockWire X, he leads the platform's mission to level the playing field by delivering real-time ASX announcement analysis and comprehensive investor education to retail and professional investors globally.
Learn More

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher